Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 119 points (0.7%) at 16,493 as of Wednesday, Jan. 15, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,941 issues advancing vs. 990 declining with 158 unchanged. The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include HCA Holdings ( HCA), down 1.0%, Grifols ( GRFS), down 1.0% and Smith & Nephew ( SNN), down 0.7%. Top gainers within the industry include Globus Medical ( GMED), up 4.6%, Edwards Life ( EW), up 3.4% and Express Scripts ( ESRX), up 0.8%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry lower today. As of noon trading, WuXi PharmaTech (Cayman is down $1.21 (-3.2%) to $36.83 on average volume. Thus far, 250,468 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 626,100 shares. The stock has ranged in price between $36.75-$38.38 after having opened the day at $38.38 as compared to the previous trading day's close of $38.04. Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.7 billion and is part of the health care sector. The company has a P/E ratio of 25.6, above the S&P 500 P/E ratio of 17.7. Shares are down 1.0% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full WuXi PharmaTech (Cayman Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.